Vigabatrin for refractory partial epilepsy

Abstract

This review of randomised controlled trials showed that vigabatrin can reduce seizure frequency in people with drug-resistant partial epilepsy. Short-term follow-up of patients showed that some side effects were associated with its use. Further analysis of longer-term observational studies is required to evaluate how likely patients are to develop visual field defects and whether such side effects are associated with dose and duration of drug use.

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentrationdependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentrationdependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…VGB is an anti-epileptic agent that is reported to be an inhibitor of gamma-aminobutyric acid breakdown. It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentration-dependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Brivaracetam add-on for refractory focal epilepsy

“…The newer drugs have been demonstrated to be more effective with respect to seizure control and associated with a higher incidence of overall adverse effects and withdrawal rates than placebo. [25][26][27][28][29][30][31][32][33][34][35][36][37] There is little evidence, however, of how these AEDs should be trialed when monotherapy fails, and in which order they should be prescribed as an adjunct, since no direct head-tohead trials are available. Although the results of this meta-analysis of randomized controlled clinical trials clearly indicated that BRV is effective to reduce the frequency of refractory partial-onset seizures and reasonably tolerated as adjunctive treatment, it cannot compare BRV to other AEDs, and the application field in the management of adult refractory epilepsy remains to be clearly established for BRV, as well as for many other newer AEDs.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentrationdependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…VGB is an anti-epileptic agent that is reported to be an inhibitor of gamma-aminobutyric acid breakdown. It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentration-dependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Brivaracetam add-on for refractory focal epilepsy

“…The newer drugs have been demonstrated to be more effective with respect to seizure control and associated with a higher incidence of overall adverse effects and withdrawal rates than placebo. [25][26][27][28][29][30][31][32][33][34][35][36][37] There is little evidence, however, of how these AEDs should be trialed when monotherapy fails, and in which order they should be prescribed as an adjunct, since no direct head-tohead trials are available. Although the results of this meta-analysis of randomized controlled clinical trials clearly indicated that BRV is effective to reduce the frequency of refractory partial-onset seizures and reasonably tolerated as adjunctive treatment, it cannot compare BRV to other AEDs, and the application field in the management of adult refractory epilepsy remains to be clearly established for BRV, as well as for many other newer AEDs.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentrationdependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Depressive Effectiveness of Vigabatrin (y-Vinyl-GABA), an Antiepileptic Drug, in Intermediate-conductance Calcium-Activated Potassium Channels in Human Glioma Cells

“…VGB is an anti-epileptic agent that is reported to be an inhibitor of gamma-aminobutyric acid breakdown. It has been approved for use as an adjunctive treatment for resistant epilepsy, and as a monotherapy for infantile spasms or West syndrome [2,3]. In the current study, we found that VGB concentration-dependently reduced the probability of IK Ca -channel openings, and that this reduction in channel activity is closely associated with an increase in mean closed time of the channel.…”

Brivaracetam add-on for refractory focal epilepsy

“…The newer drugs have been demonstrated to be more effective with respect to seizure control and associated with a higher incidence of overall adverse effects and withdrawal rates than placebo. [25][26][27][28][29][30][31][32][33][34][35][36][37] There is little evidence, however, of how these AEDs should be trialed when monotherapy fails, and in which order they should be prescribed as an adjunct, since no direct head-tohead trials are available. Although the results of this meta-analysis of randomized controlled clinical trials clearly indicated that BRV is effective to reduce the frequency of refractory partial-onset seizures and reasonably tolerated as adjunctive treatment, it cannot compare BRV to other AEDs, and the application field in the management of adult refractory epilepsy remains to be clearly established for BRV, as well as for many other newer AEDs.…”